

Julie Bertrand

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5538852/publications.pdf>

Version: 2024-02-01

27
papers

647
citations

686830

13
h-index

610482

24
g-index

29
all docs

29
docs citations

29
times ranked

1018
citing authors

#	ARTICLE	IF	CITATIONS
1	Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 509-514.	1.3	170
2	Dependence of Efavirenz- and Rifampicin-Isoniazid-Based Antituberculosis Treatment Drug-Drug Interaction on CYP2B6 and NAT2 Genetic Polymorphisms: ANRS 12154 Study in Cambodia. Journal of Infectious Diseases, 2014, 209, 399-408.	1.9	45
3	Performance Comparison of Various Maximum Likelihood Nonlinear Mixed-Effects Estimation Methods for Dose-Response Models. AAPS Journal, 2012, 14, 420-432.	2.2	42
4	Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. Brain, 2017, 140, 1117-1127.	3.7	40
5	Population Pharmacokinetic-Pharmacogenetic Study of Nevirapine in HIV-Infected Cambodian Patients. Antimicrobial Agents and Chemotherapy, 2010, 54, 4432-4439.	1.4	38
6	Comparison of Model-Based Tests and Selection Strategies to Detect Genetic Polymorphisms Influencing Pharmacokinetic Parameters. Journal of Biopharmaceutical Statistics, 2008, 18, 1084-1102.	0.4	35
7	Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART. European Journal of Clinical Pharmacology, 2009, 65, 667-678.	0.8	35
8	Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm. Journal of Pharmacokinetics and Pharmacodynamics, 2009, 36, 317-339.	0.8	33
9	Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians. Pharmacogenetics and Genomics, 2012, 22, 868-876.	0.7	31
10	Development of a Complex Parent-Metabolite Joint Population Pharmacokinetic Model. AAPS Journal, 2011, 13, 390-404.	2.2	22
11	Can a Flavored Spray (Pill Glide) Help Children Swallow Their Medicines? A Pilot Study. Pediatrics, 2016, 138, e20160680-e20160680.	1.0	18
12	A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer's disease. Psychopharmacology, 2016, 233, 3371-3381.	1.5	18
13	Therapeutic D2/3 receptor occupancies and response with low amisulpride blood concentrations in very late-onset schizophrenia-like psychosis (VLOSLP). International Journal of Geriatric Psychiatry, 2018, 33, 396-404.	1.3	18
14	Some Alternatives to Asymptotic Tests for the Analysis of Pharmacogenetic Data Using Nonlinear Mixed Effects Models. Biometrics, 2012, 68, 146-155.	0.8	13
15	Multiple single nucleotide polymorphism analysis using penalized regression in nonlinear mixed-effect pharmacokinetic models. Pharmacogenetics and Genomics, 2013, 23, 167-174.	0.7	13
16	A Population Approach to Guide Amisulpride Dose Adjustments in Older Patients With Alzheimer's Disease. Journal of Clinical Psychiatry, 2017, 78, e844-e851.	1.1	13
17	Bayesian inference using Hamiltonian Monte Carlo algorithm for nonlinear joint modeling in the context of cancer immunotherapy. Statistics in Medicine, 2020, 39, 4853-4868.	0.8	11
18	Towards safer risperidone prescribing in Alzheimer's disease. British Journal of Psychiatry, 2021, 218, 268-275.	1.7	9

#	ARTICLE	IF	CITATIONS
19	Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100â€‰mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2120-2128.	1.3	7
20	Modelling the association between biomarkers and clinical outcome: An introduction to nonlinear joint models. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1452-1463.	1.1	6
21	Comparison of Nonlinear Mixed Effects Models and Noncompartmental Approaches in Detecting Pharmacogenetic Covariates. <i>AAPS Journal</i> , 2015, 17, 597-608.	2.2	5
22	Bayesian Individual Dynamic Predictions with Uncertainty of Longitudinal Biomarkers and Risks of Survival Events in a Joint Modelling Framework: a Comparison Between Stan, Monolix, and NONMEM. <i>AAPS Journal</i> , 2020, 22, 50.	2.2	5
23	Integrating dynamic mixed-effect modelling and penalized regression to explore genetic association with pharmacokinetics. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 231-238.	0.7	3
24	Genetics of Nevirapine Metabolic Pathways at Steady State in HIV-Infected Cambodians. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	3
25	Bioequivalence and Statistics in Clinical Pharmacology. <i>Journal of Biopharmaceutical Statistics</i> , 2019, 29, 728-729.	0.4	3
26	New Modelâ€‘Based Bioequivalence Statistical Approaches for Pharmacokinetic Studies with Sparse Sampling. <i>AAPS Journal</i> , 2020, 22, 141.	2.2	3
27	Impact of study design and statistical model in pharmacogenetic studies with geneâ€‘treatment interaction. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 340-349.	1.3	1